In view of the pivotal role of CB1R in the pathogenesis of NAFLD and T2D, targeting the disease-activated CB1Rs in the liver is an attractive strategy to stop or reverse these pathologies. The gene discussed is CNR1; the disease is metabolic dysfunction-associated steatotic liver disease.